deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04176848

CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

A Phase II Study of CFI-400945 and Durvalumab in Patients With Advanced/Metastatic Triple Negative Breast Cancer (TNBC)

Sponsor: AstraZeneca

Conditions Breast Cancer
Interventions CFI-400945 Durvalumab
Updated 19 times since 2019 Last updated: Jan 29, 2026 Started: Aug 10, 2020 Primary completion: Sep 15, 2022 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04176848, this PHASE2 trial focuses on Breast Cancer and remains ongoing. Sponsored by AstraZeneca, it has been updated 19 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Dec 2019 – ~Jul 2020 · 7 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Dec 2021 · 6 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Jul 2022 · 5 months · monthly snapshot~Jul 2022 – ~Feb 2024 · 19 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

19 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Oct 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

▶ Show 14 earlier versions

  1. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Unknown → Active Not Recruiting

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Feb 2024 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: Active Not Recruiting → Unknown Status

  4. Jul 2022 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  7. Jun 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  8. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  9. Mar 2021 — May 2021 [monthly]

    Recruiting PHASE2

  10. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  11. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  12. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  13. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  14. Dec 2019 — Jul 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Canadian Cancer Trials Group
  • University Health Network, Toronto
Data source: Canadian Cancer Trials Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations